Genotype-directed Targeted Therapy for Pediatric Vascular Malformations: A Systematic Review
Journal of Indian Association of Pediatric Surgeons · 2026-07 · 31 (4) · 513-524
DOI: 10.4103/jiaps.jiaps_58_26 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Indian Association of Pediatric Surgeons, online erschienen am 02.07.2026. Verfasst von Bitesh Kumar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, AIIMS, New Delhi, India. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A BSTRACT Background: Pediatric vascular malformations are rare, heterogeneous disorders increasingly driven by somatic mutations affecting key molecular pathways, particularly the PI3K–AKT–mTOR and RAS–MAPK signaling cascades. Advances in genomic profiling have enabled the use of targeted pharmacological therapies, but the available evidence remains fragmented.
Objective
To systematically review the clinical outcomes and safety of genotype-directed targeted systemic therapies in pediatric patients with genetically characterized vascular malformations.
Methods
A systematic literature search was conducted in PubMed, Embase, and Scopus from database inception to November 21, 2025. Eligible studies included case reports, case series, cohort studies, and prospective investigations reporting genotype-directed targeted therapy in patients aged 0–18 years. Data on genetic alterations, targeted therapies, clinical and radiologic outcomes, and adverse events were extracted and synthesized qualitatively.
Results
Fifty-two studies were included, reporting pediatric patients from the neonatal period to 18 years of age. The most frequently identified genetic alterations involved the PI3K–AKT–mTOR and RAS–MAPK pathways, predominantly PIK3CA and RAS-pathway mutations. Sirolimus, alpelisib, and trametinib were the most commonly used targeted agents. Many patients demonstrated clinical improvement and radiologic stabilization or lesion reduction following targeted therapy. Grade 3–4 adverse events were uncommon and generally manageable with dose modification or temporary treatment interruption.
Conclusions
Genotype-directed targeted therapies appear to provide clinical and radiologic benefit in pediatric vascular malformations with acceptable safety profiles. However, the current evidence is largely derived from observational studies and requires prospective validation through standardized investigations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Surgery, AIIMS, New Delhi, India.
- Department of Ophthalmology, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, India.
- Department of Microbiology, Santosh Deemed to be University, Ghaziabad, Uttar Pradesh, India.
Zitieren
APA
Kumar, B., Patil, N., Goel, P., Jain, V., Yadav, D. K., Dhua, A. K., Jain, D., & Singh, S. (2026). Genotype-directed Targeted Therapy for Pediatric Vascular Malformations: A Systematic Review. Journal of Indian Association of Pediatric Surgeons, 31(4), 513-524. https://doi.org/10.4103/jiaps.jiaps_58_26
Vancouver
Kumar B, Patil N, Goel P, Jain V, Yadav DK, Dhua AK, et al. Genotype-directed Targeted Therapy for Pediatric Vascular Malformations: A Systematic Review. Journal of Indian Association of Pediatric Surgeons. 2026;31(4):513-524. doi:10.4103/jiaps.jiaps_58_26
BibTeX
@article{Kumar2026,
author = {Kumar, Bitesh and Patil, Nidhi and Goel, Prabudh and Jain, Vishesh and Yadav, Devendra Kumar and Dhua, Anjan Kumar and Jain, Divya and Singh, Shubhendu},
title = {Genotype-directed Targeted Therapy for Pediatric Vascular Malformations: A Systematic Review},
journal = {Journal of Indian Association of Pediatric Surgeons},
year = {2026},
volume = {31},
number = {4},
pages = {513--524},
doi = {10.4103/jiaps.jiaps_58_26}
}
EUVIMED